In addition to antiproliferative effect on HER2+ breast cancer cells, DCZ3112 resolved its resistance to traditional HSP90 inhibitors, providing a therapeutic potential to develop anti-breast cancer drugs.523. This evidence concerns the gene HSP90AA1 and breast carcinoma.